Strategic advisory for frontier biotech and FDA-regulated healthcare, grounded in three decades co-founding, operating, and exiting these companies. The regulatory pathway, the capital plan, and the board come from the same operator.
Advisory that connects the science to the pathway to the capital, because the same person has run all three.
FDA pathway selection and sequencing, including 351(a) BLA, RMAT designation, 510(k), and pre-IND strategy for frontier biotech and devices.
Frontier biotech investment thesis, scientific and regulatory diligence, and risk framing for investors and family offices.
Capital deployment, burn discipline, and the operating cadence that turns a thesis into a company.
Board director or board observer seats where regulatory, operating, and capital judgment are needed in the room.
A focused review of pathway options and sequencing for a specific program.
Ongoing strategic counsel across regulatory, capital, and operations.
A seat at the table for regulatory and operating judgment.
Independent diligence on a biotech thesis or transaction.
The pathway is decided first. Everything else, capital, hiring, and timeline, is built on top of it, not wrapped around it later.
Discipline with capital is a competitive advantage. The companies that survive are the ones that respect the burn.
The science changes and the markets turn. The relationships, built over three decades, are what compound.
Tell me about the program or the thesis. I will tell you whether I am the right person to help.
Connect on LinkedIn